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Background: The stem cell therapy offers a promising approach to reduce the short-term mortality rate associated with heart failure after acute 
myocardial infarction (AMI). We analyzed histological and functional effects of intracoronary administration of allogeneic adipose tissue-derived stem 
cells (ADSCs) in a porcine model of AMI.
Methods: ADSCs were isolated from 6 donor pigs and labeled by transfection. AMI was induced by occlusion of the left anterior descending artery. 
Animals that survived the AMI induction (24/26) received: culture medium on the same day of AMI (n = 6); ADSCs on the same day of AMI (n = 6), 
culture medium 7 days after AMI (n = 6), or ADSCs 7 days after AMI (n = 6). At three weeks follow-up, cardiac function and alloantibodies formation 
were tested. Histological analysis was performed to study ADSCs implantation and differentiation, vascular density,T cells and vascular endothelial 
growth factor expression.
Results: The administration of ADSCs on the same day and 7 days after AMI resulted in similar rates of engrafted cells and some of these cells 
expressed endothelial cells, smooth muscle cells and cardiomyocytes markers. ADSCs administered on the same day of AMI compared to that 
administered at 7 days after AMI was more effective in increasing: new vessel formation (249±64 vs 161±37 vessels/mm2; P<0,05), T lymphocytes 
presence (1±0.4 vs 0.4±0.3 % area CD3+; P<0,05) and expression of vascular endothelial growth factor (32±7 vs 20±4 % area VEGF +). Allogeneic 
ADSCs therapy did not affect ejection fraction and induced the formation of alloantibodies
Conclusions: The allogeneic ADSCs in our experimental model did not behave as immunoprivileged and elicits a humoral and cellular immune 
response. The timing of ADSCs administration after AMI did not influence either the low rates of ADSCs implantation and differentiation or the 
percentage of animals that developed humoral rejection. However, administration of ADSCs on the same day of AMI augmented cellular rejection and 
was more effective in increasing expression of vascular endothelial growth factor and neovascularisation.
